Abstract
The recombinant technology made it possible to produce large amounts of interferons (IFNs), to characterize different human IFN subtypes, and to exploit their therapeutic potential [1]. In 1981, nearly a decade after the introduction of IFNs into the clinic, Treuner was the first to recognize the development of IFN antibodies as a typical side effect of IFN treatment in humans. He reported on a patient with nasopharyngeal carcinoma who developed neutralizing IgG antibodies to IFN-β under IFN-β therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Nagata N, Mantei C, Weismann C (1980) The structure of one of the eight or more distinct chromosomal genes for human interferon-α. Nature 287: 401–408
Treuner J, Niethammer D, Dannecker G, Hajman R, Nee fV, Hofschneider PH (1980) Sucessful treatment of nasopharyngeal carcinoma with interferon. Lancet 1: 817–818
Gutterman JU, Fine S, Quesada JR, Harning S, Levine JF, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown PW, Merigan T, Dziewanowski Z (1982) Recombinant leukocyte A interferon: pharmakokinetics, single dose tolerance and biological effects in cancer patients. Ann Intern Med 96: 549–556
Quesada JR, Rios A, Swanson D, Gutterman JU (1985) Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 3: 1522–1528
Spiegel RJ, Spicehandler JR, Jacobs SL, Oden ME (1986) Low incidence of serum neutralizing factors in patients receiving recombinant alpha-2b interferon. Am J Med 80: 223–228
Itri LM, Campion M, Dennin R, Palleroni A, Gutterman JU, Groopman J, Trowa PW (1987) Incidence and clinical significance of neutralizing antibodies in patients receiving Roferon A by intramuscular injection. Cancer 59: 668–674
Talpaz M, McCredrie KB, Maoliget GM, Gutterman JU (1983) Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62: 689–695
Ho M, Enders JF (1959) An inhibitor of viral activity appearing in infected cell cultures. Proc Natl Acad Sci USA 45: 383–389
Strander H, Cantell K, Carlstrom G, Jacobsen PA (1973) Clinical and laboratory investigations in man: systemic administration of potent interferon in man. JNCI 51: 733–742
Ingimarsson S, Cantell K, Carlstrom G, Dalton B, Paucher K, Strander H (1981) Immune reactions and long-term therapy with human leukocyte interferon. Acta Med Scand 209: 17–19
WHO Expert Committee on Biological Standardization. 35th report, pp 50–53
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
von Wussow, P., Freund, M., Hartmann, F., Diedrich, H., Poliwoda, H., Deicher, H. (1988). Clinical Significance of Neutralizing Antibodies in Patients with Chronic Myelogenic Leukemia. In: Huhn, D., Hellriegel, K.P., Niederle, N. (eds) Chronic Myelocytic Leukemia and Interferon. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73526-4_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-73526-4_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-19067-7
Online ISBN: 978-3-642-73526-4
eBook Packages: Springer Book Archive